Lower serum antibodies against tau protein and heavy neurofilament in Alzheimer disease

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023752%3A_____%2F18%3A43919424" target="_blank" >RIV/00023752:_____/18:43919424 - isvavai.cz</a>

Výsledek na webu

<a href="https://content.iospress.com/articles/journal-of-alzheimers-disease/jad180039" target="_blank" >https://content.iospress.com/articles/journal-of-alzheimers-disease/jad180039</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3233/JAD-180039" target="_blank" >10.3233/JAD-180039</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Lower serum antibodies against tau protein and heavy neurofilament in Alzheimer disease

Popis výsledku v původním jazyce

Background. Unlike antibodies against beta-amyloid, little is known about serum antibodies to neuron- and disease-specific cytoskeletal proteins in patients with Alzheimer disease (AD). Moreover, fluctuations of these antibodies over time are not known, neither. Patients and methods. Antibodies against three targets (tau, light (NFL) and heavy (NFH) neurofilaments) were measured using ELISA in 100 serum samples from 51 cognitively normal elderly controls (NC) and 49 patients with AD fulfilling NINCDS-ADRDA criteria. We also measured all three anti-neurocytoskeletal antibodies in paired serum samples from 48 NC and 11 AD patients after 562?161 days in NC and after 441?253 days in AD. Results. The AD patients had significantly lower levels of anti-tau antibodies (p = 0.03) and more anti-NFH antibodies (p = 0.005) than those in the control group at baseline. On the contrary, anti-NFL antibodies or total IgG concentrations in serum did not differ. All three antibodies remained stable in both groups except for a selective and significant anti-tau decline in AD patients (p = 0.03). Conclusions. The different responses to these antigens suggest some antibody selectivity in AD. The significant decline was observed for only serum anti-tau antibodies in AD patients over time and it corresponds to lower levels in these patients. Our findings indicate a novel and special feature of disease-relevant antigens and humoral autoimmunity in AD.

Název v anglickém jazyce

Lower serum antibodies against tau protein and heavy neurofilament in Alzheimer disease

Popis výsledku anglicky

Background. Unlike antibodies against beta-amyloid, little is known about serum antibodies to neuron- and disease-specific cytoskeletal proteins in patients with Alzheimer disease (AD). Moreover, fluctuations of these antibodies over time are not known, neither. Patients and methods. Antibodies against three targets (tau, light (NFL) and heavy (NFH) neurofilaments) were measured using ELISA in 100 serum samples from 51 cognitively normal elderly controls (NC) and 49 patients with AD fulfilling NINCDS-ADRDA criteria. We also measured all three anti-neurocytoskeletal antibodies in paired serum samples from 48 NC and 11 AD patients after 562?161 days in NC and after 441?253 days in AD. Results. The AD patients had significantly lower levels of anti-tau antibodies (p = 0.03) and more anti-NFH antibodies (p = 0.005) than those in the control group at baseline. On the contrary, anti-NFL antibodies or total IgG concentrations in serum did not differ. All three antibodies remained stable in both groups except for a selective and significant anti-tau decline in AD patients (p = 0.03). Conclusions. The different responses to these antigens suggest some antibody selectivity in AD. The significant decline was observed for only serum anti-tau antibodies in AD patients over time and it corresponds to lower levels in these patients. Our findings indicate a novel and special feature of disease-relevant antigens and humoral autoimmunity in AD.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30103 - Neurosciences (including psychophysiology)

Projekt

<a href="/cs/project/LO1611" target="_blank" >LO1611: Udržitelnost pro Národní ústav duševního zdraví</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Alzheimer´s Disease

ISSN

1387-2877

e-ISSN

—

Svazek periodika

64

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

10

Strana od-do

751-760

Kód UT WoS článku

000437257500006

EID výsledku v databázi Scopus

2-s2.0-85049687560